Rani Therapeutics Holdings (RANI) Common Equity (2020 - 2025)
Historic Common Equity for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q3 2025 value amounting to -$12.0 million.
- Rani Therapeutics Holdings' Common Equity fell 30732.47% to -$12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.0 million, marking a year-over-year decrease of 30732.47%. This contributed to the annual value of $3.5 million for FY2024, which is 8627.13% down from last year.
- According to the latest figures from Q3 2025, Rani Therapeutics Holdings' Common Equity is -$12.0 million, which was down 30732.47% from -$9.2 million recorded in Q2 2025.
- Rani Therapeutics Holdings' Common Equity's 5-year high stood at $131.7 million during Q3 2021, with a 5-year trough of -$123.7 million in Q2 2021.
- In the last 5 years, Rani Therapeutics Holdings' Common Equity had a median value of $30.1 million in 2023 and averaged $37.4 million.
- In the last 5 years, Rani Therapeutics Holdings' Common Equity skyrocketed by 20725.96% in 2021 and then crashed by 30732.47% in 2025.
- Quarter analysis of 5 years shows Rani Therapeutics Holdings' Common Equity stood at $121.6 million in 2021, then crashed by 39.12% to $74.0 million in 2022, then tumbled by 65.62% to $25.4 million in 2023, then plummeted by 86.27% to $3.5 million in 2024, then crashed by 442.77% to -$12.0 million in 2025.
- Its last three reported values are -$12.0 million in Q3 2025, -$9.2 million for Q2 2025, and -$5.3 million during Q1 2025.